Industry: 'Learn From COVID And Cut EU Drug Review Times'
Change Could Help In Reimbursement And Access Decisions
Executive Summary
A report commissioned by the European pharmaceutical industry body EFPIA has come up with some suggestions for reducing the time the European Commission takes to issue marketing authorizations for cancer drugs – and possibly other products too.
You may also be interested in...
Top EU Regulator Attacks Complexity & Duplication In European System
Industry and agency speakers at the DIA Europe 2022 conference voiced a litany of complaints about the EU’s drug regulatory framework, saying it has failed to keep up with developments in science and that too much assessment work is being duplicated.
From Innovation Mindsets To Incentives And COVID-19 Lessons: How EU Pharma Legislation Should Evolve
If the EU wants to become a more competitive space for innovation it can take a few lessons from both the US and the COVID-10 pandemic, say European pharma industry representatives. Fostering better communication between regulators and companies is just one example.
EFPIA On How EU Can Become A ‘World Leader’ In Life Sciences
More agile regulatory processes, a much shorter period for the European Commission to make new drug approval decisions, and a firm legal basis for the European Medicines Agency in assessing combination products. These are among proposals put forward by Europe’s R&D-based pharmaceutical industry amid moves to revise the EU medicines legislation.